ABOUT THIS EVENT This symposium will address drug development of products that contain nanomaterials in their formulation and how the newly finalized guidance to industry for products that contain nanomaterials can be implemented in filings to the FDA. FDA speakers will present reviewer perspectives on drug development and laboratory efforts to facilitate further understanding of challenges to manufacture products that contain nanomaterials. Two additional speakers will address safety evaluations of foods to contact surfaces that contain nanomaterials and the development of standard materials and methods for nanomaterials. - FDA will discuss the primary Chemistry Manufacturing and Controls (CMC) and nonclinical hurdles for developing products that contain nanomaterials
- FDA will provide case studies on the development of the COVID mRNA lipid nanoparticle vaccine products
- FDA will present efforts to establish standards and standard methods for monitoring products that contain nanomaterials
TOPICS COVERED | | INTENDED AUDIENCE - Regulatory science and regulatory affairs professionals working on drug products, including biologicals, that contain nanomaterials and submit IND/NDA/BLA/ANDA applications for FDA review
- Researchers working on applications of nanotechnology for pharmaceutical products, analytical methodology for control of pharmaceuticals that contain nanomaterials, and nonclinical studies to support human clinical trials
- Foreign regulators who review comparable pharmaceutical products that contain nanomaterials
| |
No comments:
Post a Comment